Curated News
By: NewsRamp Editorial Staff
March 16, 2026
Sartorius Launches Eveo Platform to Revolutionize Cell Therapy Manufacturing
TLDR
- Sartorius's Eveo platform gives companies a competitive edge by quadrupling cell therapy output in existing space while cutting manufacturing costs by 90 percent.
- The modular Eveo system integrates cell selection, activation, expansion, and quality control into a closed, automated platform that processes eight patient batches simultaneously.
- This technology expands patient access to life-saving cell therapies by reducing costs and production bottlenecks, making transformative treatments available to more people worldwide.
- A single operator can now produce over 350 cell therapy doses annually in space that previously yielded only 100, revolutionizing manufacturing efficiency.
Impact - Why it Matters
This development matters because it directly addresses one of the most significant barriers to making revolutionary cell therapies like CAR-T treatments accessible to patients who need them. Currently, these personalized therapies remain prohibitively expensive and limited in availability due to complex, labor-intensive manufacturing processes that require specialized facilities and highly trained personnel. By potentially reducing manufacturing costs by 90% and quadrupling production capacity in existing spaces, the Eveo platform could dramatically expand patient access to treatments that have shown remarkable success against certain cancers and other diseases. This represents a crucial step toward democratizing advanced medical treatments that have been largely restricted to limited patient populations due to cost and logistical constraints. As cell therapies continue to advance, scalable manufacturing solutions like this will be essential for translating laboratory breakthroughs into widely available clinical treatments.
Summary
In a groundbreaking development for the biopharmaceutical industry, the life science group Sartorius has unveiled its innovative Eveo Cell Therapy Platform, designed to revolutionize the production of autologous cell therapies like CAR-T treatments. This integrated system addresses critical manufacturing bottlenecks that have historically limited patient access to these transformative therapies by combining automated, multi-parallel production with quality control into a single, scalable platform. Key players include Sartorius, a leading international partner to biopharmaceutical research and manufacturing, and ElevateBio, a prominent cell therapy CDMO that collaborated on a successful pilot project proving the platform's real-world applicability.
The core message from Sartorius executive Rene Faber emphasizes that while cell therapies are redefining medical possibilities, their accessibility remains constrained by complex, expensive, and capacity-limited manufacturing processes. The Eveo platform tackles these structural challenges head-on by integrating cell selection, activation, gene modification, expansion, and final formulation into a closed system using Sartorius solutions from raw materials to bioreactors. Its compact design allows implementation in existing facilities with existing staff, potentially increasing output up to fourfold in the same cleanroom space and reducing manufacturing costs by around 90 percent in CAR-T processes. The system also incorporates Sartorius' capabilities in live cell imaging and high throughput flow cytometry to address quality control bottlenecks.
Sartorius plans to begin taking orders for the Eveo Cell Therapy Platform in September 2026, with first deliveries expected in 2027. ElevateBio will be granted access to one of the first platforms as a preferred partner. This innovation strengthens Sartorius' position in the dynamic advanced therapies market and represents a significant step toward making life-saving cell therapies more accessible to patients worldwide. For more information, visit the company's newsroom and follow them on LinkedIn, or check the original release on www.newmediawire.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Sartorius Launches Eveo Platform to Revolutionize Cell Therapy Manufacturing
